NZ581362A - Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use - Google Patents

Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Info

Publication number
NZ581362A
NZ581362A NZ581362A NZ58136208A NZ581362A NZ 581362 A NZ581362 A NZ 581362A NZ 581362 A NZ581362 A NZ 581362A NZ 58136208 A NZ58136208 A NZ 58136208A NZ 581362 A NZ581362 A NZ 581362A
Authority
NZ
New Zealand
Prior art keywords
clopidogrel
sae
composition
less
composition according
Prior art date
Application number
NZ581362A
Other languages
English (en)
Inventor
Gerold L Mosher
Rebecca L Wedel
Karen T Johnson
Stephen G Machatha
Jane A Cowee
Daniel J Cushing
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of NZ581362A publication Critical patent/NZ581362A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NZ581362A 2007-04-27 2008-04-26 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use NZ581362A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91455507P 2007-04-27 2007-04-27
PCT/US2008/061697 WO2008134600A1 (en) 2007-04-27 2008-04-26 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Publications (1)

Publication Number Publication Date
NZ581362A true NZ581362A (en) 2011-07-29

Family

ID=39926106

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ581362A NZ581362A (en) 2007-04-27 2008-04-26 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use

Country Status (17)

Country Link
US (6) US8343995B2 (enExample)
EP (2) EP2152078B8 (enExample)
JP (4) JP5681485B2 (enExample)
KR (3) KR20160033792A (enExample)
CN (2) CN101686681B (enExample)
AU (1) AU2008245550B2 (enExample)
BR (1) BRPI0809838B1 (enExample)
CA (2) CA2685331C (enExample)
DK (1) DK2152078T3 (enExample)
ES (1) ES2855700T3 (enExample)
HU (1) HUE053158T2 (enExample)
IL (1) IL201776A (enExample)
MX (1) MX2009011619A (enExample)
NZ (1) NZ581362A (enExample)
RU (1) RU2470636C2 (enExample)
SI (1) SI2152078T1 (enExample)
WO (2) WO2008134600A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160033796A (ko) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
JP5592802B2 (ja) * 2008-01-25 2014-09-17 セラノスティクス ラボラトリー 薬物応答を評価するための方法および組成物
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009133455A2 (en) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Pharmaceutical composition of clodipogrel
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) * 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US8563574B2 (en) * 2009-12-07 2013-10-22 Academic Pharmaceuticals, Inc. Parenteral formulation of clopidogrel
WO2011101865A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
WO2012122493A1 (en) * 2011-03-10 2012-09-13 Jina Pharmaceuticals, Inc. Lipid based clopidogrel compositions, methods, and uses
RU2014127884A (ru) * 2011-12-09 2016-02-10 Вокхардт Лимитед Способы лечения сердечно-сосудистого нарушения
CA2861077A1 (en) * 2012-01-30 2013-08-08 Baxter International Inc. Non-anticoagulant sulfated or sulfonated polysaccharides
US9009933B2 (en) * 2012-02-02 2015-04-21 Astrid Lombardi Method to improve the appearance of a corpse and new thanatocosmetic compositions
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
CN110066351B (zh) 2012-02-28 2022-06-14 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
JP6557144B2 (ja) 2012-10-22 2019-08-07 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JP6552967B2 (ja) 2013-02-06 2019-07-31 ホアン，ジンジュン 経口および非経口送達用のクロピドグレル遊離塩基の安定な医薬組成物
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3569313A1 (en) 2013-03-15 2019-11-20 GPB Scientific, LLC On-chip microfluidic processing of particles
US10324011B2 (en) 2013-03-15 2019-06-18 The Trustees Of Princeton University Methods and devices for high throughput purification
EP3521442B1 (en) * 2013-07-15 2023-05-03 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
EP3341893A4 (en) * 2015-08-24 2019-03-06 GPB Scientific, LLC METHOD AND DEVICES FOR MULTI-STAGE CELL CLEANING AND CONCENTRATION
EP4008319B1 (en) * 2015-11-25 2024-11-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN109982574A (zh) * 2016-11-18 2019-07-05 西澳大学 味道掩蔽产品
AU2017374450B2 (en) * 2016-12-14 2023-05-11 Sk Biopharmaceuticals Co., Ltd. Parenteral liquid preparation comprising carbamate compound
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN110711180B (zh) * 2018-07-13 2022-03-29 武汉武药科技有限公司 一种替格瑞洛组合物及其制备方法
WO2020101627A1 (en) * 2018-11-14 2020-05-22 Canakkale Onsekiz Mart Universitesi Rektorlugu A solution developed to be applied to the saphenous vein graft
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
CN109674744B (zh) * 2019-01-21 2021-09-17 成都欣捷高新技术开发股份有限公司 稳定的盐酸替罗非班液体组合物及其制备方法
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
US11739952B2 (en) 2020-07-13 2023-08-29 Rheem Manufacturing Company Integrated space conditioning and water heating/cooling systems and methods thereto
US20230059869A1 (en) 2021-08-03 2023-02-23 Liqmeds Worldwide Limited Oral pharmaceutical solution of clopidogrel
US20250064886A1 (en) * 2021-12-31 2025-02-27 Hangzhou Adamerck Pharmlabs Inc. Cardiovascular and cerebrovascular drug and use thereof
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN115902237B (zh) * 2022-11-09 2024-09-27 哈尔滨医科大学 用于判断急性心肌梗死后心源性猝死的生物标志物及其应用
WO2024234014A1 (en) * 2023-05-11 2024-11-14 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US4927013A (en) * 1989-04-12 1990-05-22 Eastman Kodak Company Package for storing and remixing two materials
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5241059A (en) 1990-05-21 1993-08-31 Toppan Printing Co., Ltd. Cyclodextrin derivatives
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US5632275A (en) * 1994-09-16 1997-05-27 Scribner-Browne Medical Design Incorporated Catheter lab table pad and method for using the same
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
CN1265598A (zh) * 1997-06-05 2000-09-06 伊莱利利公司 治疗血栓形成性疾病的方法
PT986403E (pt) 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
ES2257795T3 (es) * 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
FR2769313B1 (fr) 1997-10-06 2000-04-21 Sanofi Sa Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
DE19836021A1 (de) 1998-08-10 2000-03-09 Weitmann & Konrad Fa Pudervorrichtung
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CA2703697C (en) 2000-07-06 2012-09-04 Daiichi Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
JP4874482B2 (ja) 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CN100341506C (zh) 2000-12-25 2007-10-10 三共株式会社 含有阿斯匹林的药用组合物
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
WO2003002152A2 (en) 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
HUP0200438A3 (en) 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
CN1649616A (zh) * 2002-03-01 2005-08-03 希龙公司 治疗缺血的方法和组合物
ITMI20020933A1 (it) * 2002-05-03 2003-11-03 Danimite Dipharma S P A Procedimento per la sintesi di clopidogrel
JP2005527302A (ja) * 2002-05-24 2005-09-15 アンジオテック インターナショナル アーゲー 医療用移植物をコーティングするための組成物および方法
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
BR0314269A (pt) * 2002-09-13 2005-07-26 Cydex Inc Cápsulas contendo composições aquosas de recheio estabilizadas com ciclodextrina derivatizada
WO2004031143A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
MXPA05003591A (es) 2002-10-09 2005-09-30 Insert Therapeutics Inc Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10305984A1 (de) 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2003216707A1 (en) * 2003-03-10 2004-09-30 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
WO2004081016A1 (en) * 2003-03-12 2004-09-23 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
EP1660183A2 (en) 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
CN1976679B (zh) 2003-12-31 2011-08-31 锡德克斯药物公司 含有磺基烷基醚环糊精以及皮质甾类的吸入制剂
SI21748A (sl) * 2004-03-26 2005-10-31 Diagen D.O.O. Inkluzijski kompleksi klopidogrela in njegovih kislinskih adicijskih soli, postopek za njihovo pripravo, farmacevtski pripravki, ki vsebujejo te komplekse in njihova uporaba za zdravljenje tromboze
CN1938319B (zh) * 2004-04-09 2010-05-12 韩美药品株式会社 结晶氯吡格雷萘磺酸盐或其水合物、其制备方法及含其的药物组合物
KR20070009671A (ko) * 2004-05-06 2007-01-18 사이덱스 인크 세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제
EP1761283A2 (en) 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
US20060047121A1 (en) * 2004-09-01 2006-03-02 Sawant Kamlesh D Novel process for preparation of clopidogrel bisulfate polymorph - Form I
KR20070052780A (ko) * 2004-09-21 2007-05-22 테바 파마슈티컬 인더스트리즈 리미티드 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
US7446200B2 (en) * 2004-10-04 2008-11-04 Usv, Ltd. Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
TW200640932A (en) 2005-02-24 2006-12-01 Teva Pharma Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
KR20080016647A (ko) 2005-06-17 2008-02-21 일라이 릴리 앤드 캄파니 프라수그렐에 대한 투여 계획
AU2006264407B2 (en) * 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
EP1940399A2 (en) 2005-08-19 2008-07-09 Eli Lilly & Company Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
KR100783286B1 (ko) * 2005-09-26 2007-12-06 주식회사종근당 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2008060934A2 (en) 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
BRPI0720248A2 (pt) 2006-12-07 2013-12-31 Lilly Co Eli Artigo de fabricação de prasugrel
KR20080055355A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
SI2123656T1 (sl) 2007-03-02 2014-09-30 Daiichi Sankyo Company, Limited Postopek izdelave hidroklorid prasugrela visoke ÄŤistosti
CA2685331C (en) * 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
WO2009018069A2 (en) 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP5137961B2 (ja) 2007-10-22 2013-02-06 株式会社アドバンテスト 周波数変換装置および直交変調器
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EP2325187A4 (en) 2008-08-02 2011-09-28 Lunan Pharm Group Corp PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF
CN101390856B (zh) 2008-11-10 2011-04-20 重庆莱美药业股份有限公司 氯吡格雷的固体制剂及其制备方法
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法

Also Published As

Publication number Publication date
RU2009143991A (ru) 2011-06-10
US10512697B2 (en) 2019-12-24
KR20150041173A (ko) 2015-04-15
JP6496381B2 (ja) 2019-04-03
IL201776A0 (en) 2010-06-16
US10034947B2 (en) 2018-07-31
KR20100017366A (ko) 2010-02-16
CN101686681A (zh) 2010-03-31
US9125945B2 (en) 2015-09-08
EP2152078B8 (en) 2021-03-17
EP3766493A1 (en) 2021-01-20
US20150025243A1 (en) 2015-01-22
CA2921601C (en) 2018-04-24
CA2921601A1 (en) 2008-11-06
US20160058786A1 (en) 2016-03-03
WO2008134600A1 (en) 2008-11-06
US20130129700A1 (en) 2013-05-23
IL201776A (en) 2016-05-31
EP2152078A4 (en) 2011-06-15
US9623045B2 (en) 2017-04-18
US20170173178A1 (en) 2017-06-22
AU2008245550B2 (en) 2013-10-10
JP2018021071A (ja) 2018-02-08
HUE053158T2 (hu) 2021-06-28
WO2008134601A1 (en) 2008-11-06
HK1212909A1 (zh) 2016-06-24
MX2009011619A (es) 2010-01-18
CN104800210B (zh) 2019-08-06
AU2008245550A1 (en) 2008-11-06
US8853236B2 (en) 2014-10-07
RU2470636C2 (ru) 2012-12-27
KR101753131B1 (ko) 2017-07-04
KR20160033792A (ko) 2016-03-28
CN101686681B (zh) 2015-04-01
BRPI0809838B1 (pt) 2021-10-05
CA2685331A1 (en) 2008-11-06
CA2685331C (en) 2016-07-05
SI2152078T1 (sl) 2021-08-31
CN104800210A (zh) 2015-07-29
JP2010525083A (ja) 2010-07-22
JP2015091857A (ja) 2015-05-14
JP5681485B2 (ja) 2015-03-11
US20180326090A1 (en) 2018-11-15
ES2855700T3 (es) 2021-09-24
EP2152078B1 (en) 2021-01-13
JP6076382B2 (ja) 2017-02-08
US20100292268A1 (en) 2010-11-18
EP3766493B1 (en) 2023-08-23
JP6228286B2 (ja) 2017-11-08
BRPI0809838A2 (pt) 2019-01-15
DK2152078T3 (da) 2021-02-08
EP2152078A1 (en) 2010-02-17
US8343995B2 (en) 2013-01-01
JP2017061533A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
US10512697B2 (en) Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
AU2014200085B2 (en) Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
AU2015255164B2 (en) Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
HK1212909B (zh) 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2016 BY CPA GLOBAL

Effective date: 20150313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2017 BY CPA GLOBAL

Effective date: 20160311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2018 BY CPA GLOBAL

Effective date: 20170311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2019 BY CPA GLOBAL

Effective date: 20180315

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2021 BY CPA GLOBAL

Effective date: 20200312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2022 BY CPA GLOBAL

Effective date: 20210312

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2023 BY CPA GLOBAL

Effective date: 20220310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2025 BY IPAN GMBH

Effective date: 20240408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 APR 2026 BY IPAN GMBH

Effective date: 20250407